The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey-Reference-Cited by-同舟云学术

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

Published:2019-01-24 Issue:3 Volume:98 Page:713-722
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Brioli Annamaria^ORCID,Klaus Maximilian,Sayer Herbert,Scholl Sebastian,Ernst Thomas,Hilgendorf Inken,Scherag André,Yomade Olaposi,Schilling Kristina,Hochhaus Andreas,Mügge Lars-Olof,von Lilienfeld-Toal Marie

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-019-03621-1/fulltext.html

Reference22 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520. https://doi.org/10.1182/blood-2007-10-116129

2. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122–1128. https://doi.org/10.1038/leu.2013.313

3. Cavo M, Zamagni E, Tosi P et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35–39. https://doi.org/10.1182/blood-2005-02-0522

4. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PRE, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, for the National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group (2012) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results. Haematologica 97:442–450. https://doi.org/10.3324/haematol.2011.043372

5. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, GIMEMA Italian Myeloma Network (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085. https://doi.org/10.1016/S0140-6736(10)61424-9

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary hypogammaglobulinemia in adults—A large retrospective cohort study;Medicina Clínica;2023-11

2. Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay;Hematology, Transfusion and Cell Therapy;2023-10

3. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel;Blood Cancer Journal;2023-08-01

4. Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study;Clinical Lymphoma Myeloma and Leukemia;2023-08

5. Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma;Internal Medicine Journal;2023-07-12